Skip to main content
Top
Published in: International Urology and Nephrology 6/2012

01-12-2012 | Nephrology – Original Paper

Renal biomarkers for assessment of kidney function in renal transplant recipients: how do they compare?

Authors: Samra Abouchacra, Ahmed Chaaban, Raafat Hakim, Nicole Gebran, Hanan El-Jack, Faiz Rashid, Yousef Boobes, Amna Muhairi, Qutaiba Hussain, Imran Khan, Fares Chedid, Nico Negelkerke

Published in: International Urology and Nephrology | Issue 6/2012

Login to get access

Abstract

Accurate assessment of renal function is of key importance, given its prognostic value. However, gold standard measures are cumbersome, and serum creatinine itself is an insensitive predictor, especially in renal transplant recipients. Though GFR-estimating formulae have been relied upon, they do have their own limitations. Nevertheless, renal biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C, among others, are now emerging as potentially useful indicators of GFR. We aimed to evaluate the diagnostic performance of NGAL versus cystatin C and eGFR using CKD-EPI, MDRD and cystatin C in renal transplant recipients and non-transplant CKD patients. We found a significant correlation between NGAL, serum creatinine, cystatin C and eGFR. The latter parameters were also strong predictors of serum NGAL levels. However, performance of NGAL, based on receiver operating characteristic curves, was inferior to that of the reference tests. It appears that in renal transplant recipients NGAL correlates well with cystatin C and eGFR, most strongly with cystatin-based formula. Though this suggests potential use of NGAL as a screening test, its weaker diagnostic performance raises some concern about its clinical usefulness. Larger studies are needed to explore this further.
Literature
1.
go back to reference Poge U, Gehardt T, Palmedo H et al (2005) MDRD equations for estimation of GFR in renal transplant recipients. Am J Transpl 5:2306CrossRef Poge U, Gehardt T, Palmedo H et al (2005) MDRD equations for estimation of GFR in renal transplant recipients. Am J Transpl 5:2306CrossRef
2.
go back to reference Matsushita K, Selvin E et al (2010) Risk implication of the new CKD Epi equation compared with MDRD study equation for eGFR The (aric study). AJKD 55(4):648–659PubMedCrossRef Matsushita K, Selvin E et al (2010) Risk implication of the new CKD Epi equation compared with MDRD study equation for eGFR The (aric study). AJKD 55(4):648–659PubMedCrossRef
3.
go back to reference White CA, Akbari A, Doucette S, Fergusson D, Knoll GA (2010) Estimating glomerular filtration rate in kidney transplantation: is the new chronic kidney disease epidemiology collaboration equation any better? Clin Chem 56(3):474–477 Epub 2009 Dec 3PubMedCrossRef White CA, Akbari A, Doucette S, Fergusson D, Knoll GA (2010) Estimating glomerular filtration rate in kidney transplantation: is the new chronic kidney disease epidemiology collaboration equation any better? Clin Chem 56(3):474–477 Epub 2009 Dec 3PubMedCrossRef
4.
go back to reference Pöge U, Gerhardt T, Stoffel-Wagner B, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP (2008) Can modifications of the MDRD formula improve the estimation of glomerular filtration rate in renal allograft recipients? NDTT 23(7):2427–2428CrossRef Pöge U, Gerhardt T, Stoffel-Wagner B, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP (2008) Can modifications of the MDRD formula improve the estimation of glomerular filtration rate in renal allograft recipients? NDTT 23(7):2427–2428CrossRef
5.
go back to reference Pöge U, Gerhardt T, Stoffel-Wagner B, Sauerbruch T (2011) Woitas RP Validation of the CKD-EPI formula in patients after renal transplantation. NDT 26(12):4104–4108PubMedCrossRef Pöge U, Gerhardt T, Stoffel-Wagner B, Sauerbruch T (2011) Woitas RP Validation of the CKD-EPI formula in patients after renal transplantation. NDT 26(12):4104–4108PubMedCrossRef
6.
go back to reference Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S. (2008)Serum NGAL as a markers of renal function in non-diabetic patients with stage 2-4 CKD. Ren Fail 2008. 30(6):625-628. Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S. (2008)Serum NGAL as a markers of renal function in non-diabetic patients with stage 2-4 CKD. Ren Fail 2008. 30(6):625-628.
7.
go back to reference Malyszko J, Bachorzewska-Gajewska H (2009) NGAL is a new and sensitive marker of kidney function in CKD patients and renal allograft recipients. Transpl Proc 41:158–161CrossRef Malyszko J, Bachorzewska-Gajewska H (2009) NGAL is a new and sensitive marker of kidney function in CKD patients and renal allograft recipients. Transpl Proc 41:158–161CrossRef
8.
go back to reference Stefan S, Michael M, Gideon H (2007) Detection of subclinical tubular injury after renal transplantation, comparison of urine protein analysis with allograft histology. Transplantation 84(1):104–112CrossRef Stefan S, Michael M, Gideon H (2007) Detection of subclinical tubular injury after renal transplantation, comparison of urine protein analysis with allograft histology. Transplantation 84(1):104–112CrossRef
9.
go back to reference Bargnoux AS, Perrin M (2011) Analytical performance of Cystatin C turbidimetric assay which impact on accuracy of glomerular filtration rate estimation in renal transplantation. Clin Chem Lab Med Bargnoux AS, Perrin M (2011) Analytical performance of Cystatin C turbidimetric assay which impact on accuracy of glomerular filtration rate estimation in renal transplantation. Clin Chem Lab Med
10.
go back to reference Delanage P, Pieroni L, Abshoff C, Lutteri L, Chapelle JP, Krzesinski JM, Hainque B, Cavalier E. (2008) Analytical study of three cystatin C assay and their impact on cystatin c-based GFR prediction equations. Clin Chem Acta 398(1–2):118–124 Delanage P, Pieroni L, Abshoff C, Lutteri L, Chapelle JP, Krzesinski JM, Hainque B, Cavalier E. (2008) Analytical study of three cystatin C assay and their impact on cystatin c-based GFR prediction equations. Clin Chem Acta 398(1–2):118–124
11.
go back to reference Hogs B, Ekart R (2006) Serum Cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transpl 21:1855–1862CrossRef Hogs B, Ekart R (2006) Serum Cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transpl 21:1855–1862CrossRef
12.
go back to reference Mishra J, Pada A, Ma Q (2003) Identification of NGAL as novel early urinary biomarker for ischemic renal injury. J Am Soc Nephro 14:2534CrossRef Mishra J, Pada A, Ma Q (2003) Identification of NGAL as novel early urinary biomarker for ischemic renal injury. J Am Soc Nephro 14:2534CrossRef
13.
go back to reference Mishra J, Pada A, Ma Q (2006) Kidney NGAL is a novel early marker of acute renal injury following transplantation. Pediatric Nephrol 21:856CrossRef Mishra J, Pada A, Ma Q (2006) Kidney NGAL is a novel early marker of acute renal injury following transplantation. Pediatric Nephrol 21:856CrossRef
14.
go back to reference Nickolas TL, O’Rourke MJ, Yang J (2008) Sensitivity and specificity of a single emergency department measurement of urinary NGAL for diagnosis of AKI. Ann Intern Med 148:810PubMed Nickolas TL, O’Rourke MJ, Yang J (2008) Sensitivity and specificity of a single emergency department measurement of urinary NGAL for diagnosis of AKI. Ann Intern Med 148:810PubMed
15.
go back to reference Bolignano D, Lacquanitii A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M (2009) NGAL and progression of chronic kidney disease. CJASN 4(2):337–344PubMed Bolignano D, Lacquanitii A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M (2009) NGAL and progression of chronic kidney disease. CJASN 4(2):337–344PubMed
16.
go back to reference National Kidney Foundation (2002) K/DOQI clinical practice guidelines for CKD: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRef National Kidney Foundation (2002) K/DOQI clinical practice guidelines for CKD: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRef
17.
go back to reference Mitsnefes MM, Kathman TS, Mishra J et al (2007) Serum neurtrophil gelatinase- associated lipocalin as a marker of renal function in children in with chronic kidney disease. Pediatr Neprhol 22:101–108CrossRef Mitsnefes MM, Kathman TS, Mishra J et al (2007) Serum neurtrophil gelatinase- associated lipocalin as a marker of renal function in children in with chronic kidney disease. Pediatr Neprhol 22:101–108CrossRef
18.
go back to reference Chandhary K (2010) The emerging role of bio-markers in diabetes and hypertensive CKD. Curr Diab Resp 10:32–42CrossRef Chandhary K (2010) The emerging role of bio-markers in diabetes and hypertensive CKD. Curr Diab Resp 10:32–42CrossRef
Metadata
Title
Renal biomarkers for assessment of kidney function in renal transplant recipients: how do they compare?
Authors
Samra Abouchacra
Ahmed Chaaban
Raafat Hakim
Nicole Gebran
Hanan El-Jack
Faiz Rashid
Yousef Boobes
Amna Muhairi
Qutaiba Hussain
Imran Khan
Fares Chedid
Nico Negelkerke
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0188-y

Other articles of this Issue 6/2012

International Urology and Nephrology 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.